Ambeed 大中华区 CN | ZH

中文 - ZH English - EN

Ambeed.cn

搜索

关键字搜索批量搜索

首页 收藏 购物车0
首页 / 抑制剂/激动剂 /
维生素D相关/核受体
内分泌学/激素
/ 雄激素受体 / Bicalutamide

比卡鲁胺 /Bicalutamide {[allProObj[0].p_purity_real_show]}

货号：A176397 同义名： 毕卡鲁胺 / ICI 176334;ZD 176334

Bicalutamide是一种口服活性、非甾体类雄激素受体（AR）拮抗剂，用于前列腺癌研究。

Bicalutamide 化学结构 CAS号：90357-06-5
Bicalutamide 化学结构
CAS号：90357-06-5
Bicalutamide 3D分子结构
CAS号：90357-06-5
Bicalutamide 化学结构 CAS号：90357-06-5
Bicalutamide 3D分子结构 CAS号：90357-06-5
规格 价格 会员价 库存 数量
{[ item.pr_size ]}

{[ getRatePrice(item.pr_rmb, 1,1) ]}

{[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ suihuo_tips(item.pr_am, item.pr_size) ]}

{[ getRatePrice(item.pr_rmb, 1,1) ]}

{[ getRatePrice(item.pr_rmb,item.pr_rate,1) ]} {[ suihuo_tips(item.pr_am, item.pr_size) ]} 		{[ getRatePrice(item.pr_rmb, 1,1) ]}{[ suihuo_tips(item.pr_am, item.pr_size) ]} {[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate) ]} 现货 咨询 - +
购物车0 收藏 询单

Bicalutamide 纯度/质量文件 产品仅供科研

货号：A176397 标准纯度： {[allProObj[0].p_purity_real_show]}
批次查询： 批次纯度:

全球学术期刊中引用的产品

• Cell Host Microbe, 2024. Ambeed. [ A163338 ]
• Cancer Res., 2024. Ambeed. [ A295334 ]
• J. Pharm. Investig., 2024. Ambeed. [ A221527 , A691302 , A272538 , A187261 ]
• J. Fungi, 2024, 10(11): 751. Ambeed. [ A796919 ]
• JBC, 2024, 107935. Ambeed. [ A194396 ]
更多 >
产品名称 Androgen Receptor ↓ 其他靶点 纯度
Cyproterone acetate ++++

Androgen Receptor, IC50: 7.1 nM

 		98%
Apalutamide +++

Androgen Receptor, IC50: 16 nM

 		98%
AZD3514 +

Androgen Receptor, Ki: 2.2 μM

 		98%
Darolutamide ++++

Androgen receptor, Ki: 11 nM

 		98%
Flutamide +++

Androgen Receptor, Ki: 55 nM

 		98%
Galeterone ++

Androgen Receptor, IC50: 384 nM

 		98%
Enzalutamide +++

Androgen Receptor, IC50: 36 nM

 		98%
Megestrol ✔ 98%
Bicalutamide ++

Androgen Receptor, IC50: 0.16 μM

 		99%
EPI-001 +

Androgen Receptor, IC50: ~6 μM

 		98%
1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多，抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用，但抑制强度暂时没有相关数据。

Bicalutamide 生物活性

靶点

  • Androgen Receptor

    Androgen Receptor, IC50:0.16 μM
描述 The androgen receptor (AR) and the androgen-AR signaling pathway play a significant role in male sexual differentiation and the development and function of male reproductive and non-reproductive organs [7]. Bicalutamide is an AR antagonist with IC50 of 0.16 μM in LNCaP/AR(cs) cell lines. In the setting of Castration-resistant prostate cancer (CRPC), bicalutamide undergoes an antagonist-to-agonist switch, stimulating AR activity and prostate tumor cell growth. In addition, bicalutamide stimulate proliferation of VCaP cells in a dose-dependent manner. The therapeutic effect of bicalutamide (10 mg/kg/d) was conducted in castrate mice bearing LNCaP/AR(cs) xenograft tumors, the antitumor activity of bicalutamide in this model was largely restricted to growth inhibition rather than tumor shrinkage [8]. Notably, Single administration of bicalutamide reduced tumor growth by 79% at defined submaximal doses [9].

Bicalutamide 细胞研究

细胞系 浓度 检测类型 检测时间 活动说明 数据源
CHO-K1 cells Function assay 2 h Displacement of [3H]mibolerone from human AR expressed in CHO-K1 cells after 2 hrs by scintillation counting, IC50=0.2 μM 20381361
COS1 cells Function assay Antagonist activity against pSG5-tagged human androgen receptor expressed in COS1 cells assessed as reduction in receptor-mediated transcriptional activity by AR-regulated rat probasin promoter fragment driven firefly luciferase reporter assay, IC50=0.0869 μM 25646649
COS7 cells Function assay Agonist activity at human androgen receptor W741C mutant expressed in COS7 cells assessed as luciferase activity after 24 hrs by reporter gene assay, EC50=0.18 μM 22094279
CV1 cells Function assay Binding affinity to human androgen receptor expressed in CV1 cells, Ki=0.151 μM 17257838

Bicalutamide 动物研究

Dose Rat: 10 mg/kg, 20 mg/kg[3] (p.o.); 1 mg/kg - 250 mg/kg[4] (p.o.) Nude mice: 150 mg/kg[5] (p.o.), 50 mg/kg - 100 mg/kg[6] (p.o.) Dog: 0.1 mg/kg - 100 mg/kg[4] (p.o.); 0.25 mg/kg, 2.5 mg/kg[4] (i.v.)
Administration p.o.
Pharmacokinetics
Animal Rats[4] Dogs[4]
Dose 50 mg/kg (male) 2.5 mg/kg
Administration p.o. p.o. or i.v.
F 0.357 66.5 ± 4.0% (p.o.)
Tmax 12 h 16.6 ± 12.7 h (p.o.)
t1/2λ 18.6 h 5.49 ± 0.53 days (p.o.)
7.47 ± 0.90 days (i.v.)
CL 54.6 ± 9.2 μl/min/kg (i.v.)
Cmax 15.4 μg/ml 2.44 ± 0.27 μg/ml (p.o.)
Vλ 0.852 ± 0.194 L/kg (i.v.)
AUC∞ 379 μg·h/ml 519 ± 34 μg·h/ml (p.o.)
796 ± 148 μg·h/ml (i.v.)

Bicalutamide 临床研究

NCT号 适应症或疾病 临床期 招募状态 预计完成时间 地点
NCT00298155 Cancer Prosta... 展开 >>te Neoplasms 收起 << Phase 2 Completed - United States, Washington ... 展开 >> Veterans' Administration Puget Sound Health Care System (VAPSHCS) Seattle, Washington, United States, 98108-1532 University of Washington Seattle, Washington, United States, 98195-6158 收起 <<
NCT00298155 - Completed - -
NCT02064036 Adenocarcinoma of the Prostate Not Applicable Recruiting October 2018 United States, California ... 展开 >> UC Davis Sacramento Cancer Center Dept of Radiation Oncology Recruiting Sacramento, California, United States, 95817 Contact: Richard Valicenti, MD    916-724-8295    rkvalicenti@ucdavis.edu    Principal Investigator: Richard Valicenti, MD 收起 <<

Bicalutamide 参考文献

[1]The Protective Role Of Ascorbic Acid Administration On The Bicalutamide Induced Reduction In Semen Quality In The Sprague - Dawley Rat

[2]Cockshott ID, Plummer GF, et al. The pharmacokinetics of Casodex in laboratory animals. Xenobiotica. 1991 Oct;21(10):1347-55.

[3]Attar RM, Jure-Kunkel M, et al. Discovery of BMS-641988, a novel and potent inhibitor of androgen receptor signaling for the treatment of prostate cancer. Cancer Res. 2009 Aug 15;69(16):6522-30.

[4]Sirotnak FM, She Y, et al. Studies with CWR22 xenografts in nude mice suggest that ZD1839 may have a role in the treatment of both androgen-dependent and androgen-independent human prostate cancer. Clin Cancer Res. 2002 Dec;8(12):3870-6.

[5]Shukla GC, Plaga AR, Shankar E, Gupta S. Androgen receptor-related diseases: what do we know? Andrology. 2016 May;4(3):366-81. doi: 10.1111/andr.12167. Epub 2016 Mar 16. PMID: 26991422.

[6]Clegg NJ, Wongvipat J, Joseph JD, Tran C, Ouk S, Dilhas A, Chen Y, Grillot K, Bischoff ED, Cai L, Aparicio A, Dorow S, Arora V, Shao G, Qian J, Zhao H, Yang G, Cao C, Sensintaffar J, Wasielewska T, Herbert MR, Bonnefous C, Darimont B, Scher HI, Smith-Jones P, Klang M, Smith ND, De Stanchina E, Wu N, Ouerfelli O, Rix PJ, Heyman RA, Jung ME, Sawyers CL, Hager JH. ARN-509: a novel antiandrogen for prostate cancer treatment. Cancer Res. 2012 Mar 15;72(6):1494-503. doi: 10.1158/0008-5472.CAN-11-3948. Epub 2012 Jan 20. PMID: 22266222; PMCID: PMC3306502.

[7]Squillace RM, Miller D, Wardwell SD, Wang F, Clackson T, Rivera VM. Synergistic activity of the mTOR inhibitor ridaforolimus and the antiandrogen bicalutamide in prostate cancer models. Int J Oncol. 2012 Aug;41(2):425-32. doi: 10.3892/ijo.2012.1487. Epub 2012 May 18. PMID: 22614157; PMCID: PMC3582879.

Bicalutamide 实验方案

计算器
存储液制备 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.32mL

0.46mL

0.23mL

11.62mL

2.32mL

1.16mL

23.24mL

4.65mL

2.32mL

Bicalutamide 技术信息

CAS号90357-06-5
分子式C18H14F4N2O4S
分子量 430.373
别名 毕卡鲁胺 ;ICI 176334;ZD 176334;Abbreviation: CDX. US brand name: Casodex. Foreign brand name: Cosudex.
运输蓝冰
存储条件

液体 -20°C:3-6个月-80°C:12个月

粉末 Keep in dark place,Sealed in dry,Room Temperature
溶解度

DMSO: 50 mg/mL(116.18 mM)，注意：DMSO长时间开封后，会吸水并导致溶解能力下降，请避免使用长期开封的DMSO
动物实验配方

IP 2% DMSO+2% Tween80+40% PEG300+water 2.2 mg/mL clear

PO 0.5% CMC-Na 26 mg/mL suspension

Tags: Bicalutamide | 90357-06-5 | Androgen Receptor | Autophagy | Androgen Receptor Inhibitor | Vitamin D Related/Nuclear Receptor | Autophagy | Androgen Receptor | Autophagy | 仅供科研使用 | AmBeed-信号通路专用抑制剂 | Bicalutamide 纯度/质量文件 | Bicalutamide 亚型比较 | Bicalutamide 生物活性 | Bicalutamide 细胞研究 | Bicalutamide 动物研究 | Bicalutamide 临床数据 | Bicalutamide 参考文献 | Bicalutamide 实验方案 | Bicalutamide 技术信息

Ambeed 相关网站 Ambeed.cn Ambeed.com
Ambeed
关于我们
联系我们
资讯中心
网站地图
产品手册
  • 批次文件查询
    • 客户支持
    技术支持
    专业术语
    缩略词释义
    质量手册
    产品咨询
    计算器
    活动政策
    订购方法
    积分商城
    活动声明
    联系我们
    400-920-2911 sales@ambeed.cn tech@ambeed.cn
    Ambeed 只为有资质的科研机构、医药企业基于科学研究或药证申报的用途提供医药研发服务，不为任何个人或者非科研性质用途提供服务。

    尊敬的 Ambeed 客户您好，
    请您选择所在区域，我们将转接对应客服为您服务！

    热门区域

    A

    B

    C

    F

    G

    H

    J

    L

    N

    Q

    S

    T

    X

    Y

    Z

    热 A B C F G H J L N Q S T X Y Z